Skip to main content
S&P 5007,711.06+1.88%DOW53,293.19+2.91%NASDAQ25,904.76+2.10%BTC$80,617.00+3.72%ETH$2,430.56+5.69%GOLD$4,076.60+3.46%OIL$88.12-8.29%
Smart Investors Daily
SID Premium
MD

NASDAQ · MDXG

MiMedx Group, Inc.

Healthcare · Biotechnology

$3.25

Up+$0.09 (+2.62%)

Updated Nov 4, 2026, 3:47 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.06B
P/E ratio
26
Dividend yield
0.00%
52-week range
$3.03 – $4.99
Volume
1.58M
Avg. volume
834.24K

Price performance · MDXG

MDXG price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

MDXG closed at $3.25 after 21 trading sessions, down 29.65% for the selected period.

Last close
$3.25
Period change
-29.65%
Period low
$3.25
Period high
$4.83
Daily close
View OHLC price history
MDXG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$3.27$3.30$3.14$3.251.58M
Nov 2, 2026$3.88$3.88$3.27$3.282.56M
Oct 30, 2026$3.98$3.99$3.79$3.882.12M
Oct 29, 2026$3.62$4.015$3.5613$3.974.04M
Oct 28, 2026$3.88$3.995$3.87$3.951.26M
Oct 27, 2026$3.86$3.90$3.79$3.901.92M
Oct 26, 2026$3.93$3.93$3.815$3.851.11M
Oct 23, 2026$3.90$3.93$3.85$3.911.26M
Oct 22, 2026$3.70$4.025$3.67$3.931.58M
Oct 21, 2026$4.20$4.20$3.73$3.742.6M
Oct 20, 2026$4.40$4.46$4.21$4.231.63M
Oct 19, 2026$4.44$4.47$4.26$4.382.69M
Oct 16, 2026$4.66$4.69$4.40$4.432.73M
Oct 15, 2026$4.76$4.875$4.655$4.681.33M
Oct 14, 2026$4.65$4.74$4.64$4.701.64M
Oct 13, 2026$4.86$4.87$4.68$4.69972.93K
Oct 12, 2026$4.68$4.84$4.63$4.83625.57K
Oct 9, 2026$4.58$4.695$4.58$4.67391.12K
Oct 8, 2026$4.58$4.625$4.475$4.621.08M
Oct 7, 2026$4.58$4.68$4.57$4.61821.15K
Oct 6, 2026$4.59$4.65$4.48$4.621.05M

Latest MDXG news

The latest Smart Investors Daily articles mentioning MDXG.

Stock researchCompany · Overview

MDXG research

Overview

Company profile and research snapshot.

Company profile

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$11.75
Implied upside
—
Analysts
—
MDXG recent ratings
DateFirmRatingTarget
Aug 27, 2026Craig-HallumBuy—
Aug 17, 2026Cantor FitzgeraldOverweight—
Apr 30, 2026CitizensMarket Outperform—
Apr 20, 2026CitizensMarket Outperform—
Apr 17, 2026Craig-HallumBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

MiMedx (MDXG) Stock Slips As Q3 Earnings Leave Profit Questions

MiMedx Group came into this Q3 2026 report under a simple thesis in many investors minds. A low P/S multiple and growth forecasts were meant to offset real concerns about ongoing losses. Then the numbers hit. The stock slipped 2% to US$3.89 today, even as the company posted US$62.3m in net sales and turned adjusted EBITDA positive at US$2m. The expectation gap sits squarely in profitability. Traders focused on another net loss of US$8.7m. The actual story is a sharp swing in earnings quality...

Yahoo · Oct 29, 2026

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx Group (NASDAQ:MDXG) reported third-quarter net sales of $62 million, down 45% from a year earlier, as continued disruption in the wound care market offset growth in its surgical business. The company said surgical revenue rose 9% year over year to $40 million, while wound care revenue decline

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By